These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15636245)

  • 1. [Immunological phenomenons in the pathology of the tear film. Is cyclosporine the turn point in the Sjögren's syndrome treatment? Preliminary report].
    Kujawa A; Rózycki R
    Klin Oczna; 2004; 106(3 Suppl):489-91. PubMed ID: 15636245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A 0,05% cyclosporine treatment of the advanced dry eye syndrome].
    Kujawa A; Rózycki R
    Klin Oczna; 2005; 107(4-6):280-6. PubMed ID: 16118939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation.
    Cordero-Coma M; Anzaar F; Sobrin L; Foster CS
    Ocul Immunol Inflamm; 2007; 15(2):99-104. PubMed ID: 17558834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
    Demiryay E; Yaylali V; Cetin EN; Yildirim C
    Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
    Barber LD; Pflugfelder SC; Tauber J; Foulks GN
    Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta2 production.
    Pflugfelder SC; De Paiva CS; Villarreal AL; Stern ME
    Cornea; 2008 Jan; 27(1):64-9. PubMed ID: 18245969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis.
    Salib GM; McDonald MB; Smolek M
    J Cataract Refract Surg; 2006 May; 32(5):772-8. PubMed ID: 16765793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tear osmolarity measurements in dry eye related to primary Sjögren's syndrome.
    Utine CA; Bıçakçıgil M; Yavuz S; Çiftçi F
    Curr Eye Res; 2011 Aug; 36(8):683-90. PubMed ID: 21780917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal.
    Rao SN
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):603-9. PubMed ID: 21999340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular surface and tear functions after topical cyclosporine treatment in dry eye patients with chronic graft-versus-host disease.
    Wang Y; Ogawa Y; Dogru M; Kawai M; Tatematsu Y; Uchino M; Okada N; Igarashi A; Kujira A; Fujishima H; Okamoto S; Shimazaki J; Tsubota K
    Bone Marrow Transplant; 2008 Feb; 41(3):293-302. PubMed ID: 17982500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes.
    Willen CM; McGwin G; Liu B; Owsley C; Rosenstiel C
    Eye Contact Lens; 2008 Jan; 34(1):43-5. PubMed ID: 18180683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.
    Su MY; Perry HD; Barsam A; Perry AR; Donnenfeld ED; Wittpenn JR; D'Aversa G
    Cornea; 2011 Oct; 30(10):1098-104. PubMed ID: 21407074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three percent diquafosol ophthalmic solution as an additional therapy to existing artificial tears with steroids for dry-eye patients with Sjögren's syndrome.
    Yokoi N; Sonomura Y; Kato H; Komuro A; Kinoshita S
    Eye (Lond); 2015 Sep; 29(9):1204-12. PubMed ID: 26160526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment.
    Wilson SE; Perry HD
    Ophthalmology; 2007 Jan; 114(1):76-9. PubMed ID: 17070588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome.
    Kim EC; Choi JS; Joo CK
    Am J Ophthalmol; 2009 Feb; 147(2):206-213.e3. PubMed ID: 18848318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic performance of tear function tests in Sjogren's syndrome patients.
    Versura P; Frigato M; Cellini M; Mulè R; Malavolta N; Campos EC
    Eye (Lond); 2007 Feb; 21(2):229-37. PubMed ID: 16397619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of topical cyclosporine, punctal occlusion, and a combination for the treatment of dry eye.
    Roberts CW; Carniglia PE; Brazzo BG
    Cornea; 2007 Aug; 26(7):805-9. PubMed ID: 17667613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of ocular surface inflammation in Sjögren syndrome.
    Hyon JY; Lee YJ; Yun PY
    Cornea; 2007 Oct; 26(9 Suppl 1):S13-5. PubMed ID: 17881909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eye.
    Byun YJ; Kim TI; Kwon SM; Seo KY; Kim SW; Kim EK; Park WC
    Cornea; 2012 May; 31(5):509-13. PubMed ID: 19730097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of an isotonic tear in combination with topical cyclosporine for the treatment of ocular surface disease.
    Hardten DR; Brown MJ; Pham-Vang S
    Curr Med Res Opin; 2007 Sep; 23(9):2083-91. PubMed ID: 17822610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.